Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
复制标题
DOI：
10.1200/jco.2008.18.1495
复制
发表时间：
2009-03-10
影响因子：
45.3
通讯作者：
Link, Brian K.
中科院分区：
文献类型：
--
作者：
Friedberg, Jonathan W.;Taylor, Michael D.;Link, Brian K.
目的滤泡性淋巴瘤（FL）的最佳治疗方法尚未确定。我们分析了一个大型的前瞻性队列研究，以确定目前的人口统计学和模式的护理FL在美国。患者和MethodsThe国家phyphoCare研究是一个多中心的，纵向的，观察性研究，旨在收集信息的治疗方案和结果，为新诊断的FL患者在美国。患者在2004年至2007年期间入组。有没有研究特定的规定治疗方案或intervention.ResultsTwo 728名受试者在265个网站，包括80%的患者从非学术网站注册。使用滤泡性淋巴瘤国际预后指数（FLIPI），三个不同的组独立的组织学分级可以定义。初始治疗策略为：观察，17.7%;利妥昔单抗单药治疗，13.9%;临床试验6.1%;放射治疗，5.6%;仅化疗，3.2%;化疗加利妥昔单抗，51.9%。化疗+利妥昔单抗方案为：利妥昔单抗+环磷酰胺、多柔比星、长春新碱、泼尼松，55.0%;利妥昔单抗+环磷酰胺、长春新碱和泼尼松，23.1%;利妥昔单抗+氟达拉滨，15.5%;其他，6.4%。选择开始治疗而不是观察与年龄、FLIPI、分期和分级相关（P
PurposeOptimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns of care of FL in the United States.Patients and MethodsThe National LymphoCare Study is a multicenter, longitudinal, observational study designed to collect information on treatment regimens and outcomes for patients with newly diagnosed FL in the United States. Patients were enrolled between 2004 and 2007. There is no study-specific prescribed treatment regimen or intervention.ResultsTwo thousand seven hundred twenty-eight subjects were enrolled at 265 sites, including the 80% of patients enrolled from nonacademic sites. Using the Follicular Lymphoma International Prognostic Index (FLIPI), three distinct groups independent of histologic grade could be defined. Initial therapeutic strategy was: observation, 17.7%; rituximab monotherapy, 13.9%; clinical trial 6.1%; radiation therapy, 5.6%; chemotherapy only, 3.2%; chemotherapy plus rituximab, 51.9%. Chemotherapy plus rituximab regimens were: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone, 55.0%; rituximab plus cyclophosphamide, vincristine, and prednisone, 23.1%; rituximab plus fludarabine based, 15.5%; other, 6.4%. The choice to initiate therapy rather than observe was associated with age, FLIPI, stage, and grade (P